BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: BAY1125976
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 79
- Registration Number
- NCT01915576
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT01915602
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT01915589
Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
Completed
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 988
- Registration Number
- NCT01914380
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice
Withdrawn
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Bayer
- Registration Number
- NCT01915264
Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT01908322
Patient and Physician Knowledge of Key Safety Messages
Completed
- Conditions
- Anticoagulation
- Interventions
- Behavioral: Rivaroxaban (Xarelto, BAY59-7939)
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2227
- Registration Number
- NCT01907048
Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 34
- Registration Number
- NCT01902264
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13
- Registration Number
- NCT01894035
Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea
Phase 3
Completed
- Conditions
- Dysmenorrhea
- Interventions
- Drug: EE20/DRSP(BAY86-5300)
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 216
- Registration Number
- NCT01892904
© Copyright 2025. All Rights Reserved by MedPath